• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

药理治疗学：代谢功能障碍相关脂肪性肝病（MAFLD）的当前趋势

Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

作者信息

Prasoppokakorn Thaninee, Pitisuttithum Panyavee, Treeprasertsuk Sombat

机构信息

Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.

Division of General Internal Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.

出版信息

J Clin Transl Hepatol. 2021 Dec 28;9(6):939-946. doi: 10.14218/JCTH.2021.00189. Epub 2021 Jul 28.

DOI:10.14218/JCTH.2021.00189
PMID:34966657
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8666366/
Abstract

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new term from nonalcoholic fatty liver disease (NAFLD) and is a positive diagnosis based on histopathology, imaging, or blood biomarkers. MAFLD is one of the common causes of liver dysfunction worldwide, likely due to the increase in metabolic syndrome as well as the high burden of disease and its relationship to other extrahepatic conditions. However, effective pharmacological therapeutic agents are still lacking; current management largely focuses on weight reduction and lifestyle modification. The purpose of this review was to summarize the updated evidence of novel therapies targeting different pathogenetic pathways in MAFLD.

摘要

代谢功能障碍相关脂肪性肝病（MAFLD）是从非酒精性脂肪性肝病（NAFLD）衍生出的一个新术语，是基于组织病理学、影像学或血液生物标志物做出的肯定性诊断。MAFLD是全球肝功能障碍的常见原因之一，这可能归因于代谢综合征的增加以及疾病的高负担及其与其他肝外疾病的关系。然而，仍然缺乏有效的药物治疗剂；目前的管理主要集中在减轻体重和改变生活方式。本综述的目的是总结针对MAFLD不同致病途径的新型疗法的最新证据。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa1c/8666366/399c40b2d65e/JCTH-9-939-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa1c/8666366/399c40b2d65e/JCTH-9-939-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa1c/8666366/399c40b2d65e/JCTH-9-939-g001.jpg

相似文献

1
Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).药理治疗学：代谢功能障碍相关脂肪性肝病（MAFLD）的当前趋势
J Clin Transl Hepatol. 2021 Dec 28;9(6):939-946. doi: 10.14218/JCTH.2021.00189. Epub 2021 Jul 28.
2
Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?代谢相关性脂肪性肝病病理生理学的当前观点：巨噬细胞是否是治疗的可行靶点？
Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):51-64. doi: 10.1080/17474124.2020.1817740. Epub 2020 Sep 17.
3
From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?从非酒精性脂肪性肝病（NAFLD）到代谢功能障碍相关脂肪性肝病（MAFLD）——儿科患者的新术语，是朝着良好科学方向迈出的一步吗？
J Clin Med. 2021 Mar 1;10(5):924. doi: 10.3390/jcm10050924.
4
Updates in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Children.儿童代谢相关脂肪性肝病（MAFLD）的研究进展。
J Pediatr Gastroenterol Nutr. 2023 Nov 1;77(5):583-591. doi: 10.1097/MPG.0000000000003919. Epub 2023 Aug 18.
5
Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm.人类相关临床前动物模型在从 NAFLD 向 MAFLD 范式转变中的应用。
Int J Mol Sci. 2022 Nov 25;23(23):14762. doi: 10.3390/ijms232314762.
6
Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.非酒精性脂肪性肝病或代谢相关脂肪性肝病诊断与心血管疾病：从流行病学到药物治疗方法。
Eur J Clin Invest. 2021 Jul;51(7):e13519. doi: 10.1111/eci.13519. Epub 2021 Mar 2.
7
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) and Viral Hepatitis.代谢功能障碍相关脂肪性肝病（MAFLD）与病毒性肝炎
J Clin Transl Hepatol. 2022 Feb 28;10(1):128-133. doi: 10.14218/JCTH.2021.00200. Epub 2021 Oct 8.
8
Epidemiology, natural history, and diagnosis of metabolic dysfunction-associated fatty liver disease: a comparative review with nonalcoholic fatty liver disease.代谢功能障碍相关脂肪性肝病的流行病学、自然史及诊断：与非酒精性脂肪性肝病的比较性综述
Ther Adv Endocrinol Metab. 2022 Dec 10;13:20420188221139650. doi: 10.1177/20420188221139650. eCollection 2022.
9
How far are we from an approved drug for nonalcoholic steatohepatitis?我们距离批准用于非酒精性脂肪性肝炎的药物还有多远？
Expert Opin Pharmacother. 2023 Jun;24(9):1021-1038. doi: 10.1080/14656566.2023.2206953. Epub 2023 May 1.
10
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies.肝纤维化与代谢相关脂肪性肝病：从分子层面到新型药理策略
Front Med (Lausanne). 2021 Oct 22;8:761538. doi: 10.3389/fmed.2021.761538. eCollection 2021.

引用本文的文献

1
The association between lifelines diet score and metabolic associated fatty liver disease: a case-control study.生命线饮食评分与代谢相关脂肪性肝病之间的关联：一项病例对照研究。
Front Nutr. 2025 May 15;12:1569814. doi: 10.3389/fnut.2025.1569814. eCollection 2025.
2
Impaired RelA signaling and lipid metabolism dysregulation in hepatocytes: driving forces in the progression of metabolic dysfunction-associated steatotic liver disease.肝细胞中RelA信号受损与脂质代谢失调：代谢功能障碍相关脂肪性肝病进展的驱动因素
Cell Death Discov. 2025 Feb 5;11(1):49. doi: 10.1038/s41420-025-02312-3.
3
Overlapping group between non-alcoholic fatty liver disease and metabolic associated fatty liver disease better for liver research.

本文引用的文献

1
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.沙格列汀，一种 PPAR-α/γ 激动剂，用于治疗非酒精性脂肪性肝病：一项随机对照、双盲 2 期试验。
Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19.
2
The efficacy of novel metabolic targeted agents and natural plant drugs for nonalcoholic fatty liver disease treatment: A PRISMA-compliant network meta-analysis of randomized controlled trials.新型代谢靶向药物和天然植物药治疗非酒精性脂肪性肝病的疗效：基于 PRISMA 共识的随机对照试验网络荟萃分析。
Medicine (Baltimore). 2021 Mar 26;100(12):e24884. doi: 10.1097/MD.0000000000024884.
3
非酒精性脂肪性肝病和代谢相关脂肪性肝病之间的重叠组对肝脏研究更有利。
JGH Open. 2024 Oct 13;8(10). doi: 10.1002/jgh3.70039. eCollection 2024 Oct.
4
N-acetylcysteine acts as a potent anti-inflammatory agent altering the eicosanoid profile in the development of simple steatosis and its progression to hepatitis.N-乙酰半胱氨酸作为一种强效抗炎剂，在单纯性脂肪变性的发展及其向肝炎的进展过程中改变类花生酸谱。
Clin Exp Hepatol. 2023 Dec;9(4):386-395. doi: 10.5114/ceh.2023.133106. Epub 2023 Dec 5.
5
Exploring the mechanism of dendrobine in treating metabolic associated fatty liver disease based on network pharmacology and experimental validation.基于网络药理学和实验验证探讨冬凌草甲素治疗代谢相关脂肪性肝病的作用机制。
Hereditas. 2024 May 16;161(1):17. doi: 10.1186/s41065-024-00322-2.
6
Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.代谢相关脂肪性肝病与慢性肾脏病的相关性：一项基于中国人群的研究。
Ren Fail. 2022 Dec;44(1):1996-2005. doi: 10.1080/0886022X.2022.2144373.
7
Healthy Lifestyle Is Associated with Reduced Mortality in Patients with Non-Alcoholic Fatty Liver Disease.健康的生活方式与非酒精性脂肪性肝病患者的死亡率降低有关。
Nutrients. 2022 Sep 14;14(18):3785. doi: 10.3390/nu14183785.
8
Obesity Management in the Primary Prevention of Hepatocellular Carcinoma.肝细胞癌一级预防中的肥胖管理
Cancers (Basel). 2022 Aug 22;14(16):4051. doi: 10.3390/cancers14164051.
9
A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.一种新的基于 MAFLD 和纤维化评分的风险分层策略在大型美国人群中的应用。
Hepatol Int. 2022 Aug;16(4):835-845. doi: 10.1007/s12072-022-10362-3. Epub 2022 Jun 14.
10
Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.马来西亚胃肠病学和肝脏病学会关于代谢功能障碍相关脂肪性肝病的共识声明。
J Gastroenterol Hepatol. 2022 May;37(5):795-811. doi: 10.1111/jgh.15787. Epub 2022 Feb 8.
Nonalcoholic Fatty Liver Disease and Recent Guideline Updates.
非酒精性脂肪性肝病与近期指南更新
Clin Liver Dis (Hoboken). 2021 Feb 1;17(1):23-28. doi: 10.1002/cld.1045. eCollection 2021 Jan.
4
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model.非甾体类法尼醇X受体激动剂西洛菲克改善大鼠非酒精性脂肪性肝炎模型的门静脉高压并减轻肝纤维化
Biomedicines. 2021 Jan 9;9(1):60. doi: 10.3390/biomedicines9010060.
5
A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD.一个缩写中的一个字母变化：从非酒精性脂肪性肝病 (NAFLD) 到代谢相关性脂肪性肝病 (MAFLD) 的信号、原因、承诺、挑战和前进步骤。
Expert Rev Gastroenterol Hepatol. 2021 Apr;15(4):345-352. doi: 10.1080/17474124.2021.1860019. Epub 2020 Dec 9.
6
A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.一项安慰剂对照试验评估皮下司美格鲁肽在非酒精性脂肪性肝炎中的疗效。
N Engl J Med. 2021 Mar 25;384(12):1113-1124. doi: 10.1056/NEJMoa2028395. Epub 2020 Nov 13.
7
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis.一项沙格列汀治疗非酒精性脂肪性肝炎患者的 2 期双盲、随机对照临床试验。
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051. Epub 2020 Nov 2.
8
A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.一项随机、双盲、安慰剂对照、多中心、剂量范围、概念验证、为期 24 周的兰尼非班治疗非酒精性脂肪性肝炎成年患者的研究：NATIVE 研究的设计。
Contemp Clin Trials. 2020 Nov;98:106170. doi: 10.1016/j.cct.2020.106170. Epub 2020 Oct 8.
9
The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.亚太肝病学会代谢相关性脂肪性肝病临床诊疗指南。
Hepatol Int. 2020 Dec;14(6):889-919. doi: 10.1007/s12072-020-10094-2. Epub 2020 Oct 1.
10
From NAFLD to MAFLD: Implications of a Premature Change in Terminology.从非酒精性脂肪性肝病到代谢相关脂肪性肝病：术语过早改变的影响。
Hepatology. 2021 Mar;73(3):1194-1198. doi: 10.1002/hep.31420. Epub 2021 Feb 6.